New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
16:25 EDTCAPR, CAPR, CAPRCapricor Therapeutics to host business news update conference call
Dr. Linda Marbán, Chief Executive Officer, provides an update on the Company's lead product candidate, CAP-1002 and discusses other Company updates on a conference call to be held on May 15 at 4:30 pm. Webcast Link
News For CAPR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2015
08:20 EDTCAPRCapricor Therapeutics granted FDA orphan drug designatoin for CAP-1002
Capricor Therapeutics announced that it has been granted orphan drug designation by the FDA for its cell therapeutic product candidate, CAP-1002, for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy. Cardiosphere-derived cells, also known as CAP-1002, are a potential therapeutic approach for the treatment of Duchenne muscular dystrophy-associated cardiomyopathy. The cells have been shown to promote cardiomyogenesis and angiogenesis, while inhibiting oxidative stress, inflammation and fibrosis in preclinical studies. Pre-clinical data demonstrated that cardiac function and exercise capacity improved in CDC-treated mdx mice, accompanied by attenuation of inflammation, improved mitochondrial function and a reduction in collagen content and fibrosis in CDC-treated mdx hearts. The findings raise the possibility that CDCs may be useful therapeutically for heart failure in patients with Duchenne muscular dystrophy.
April 21, 2015
13:04 EDTCAPRCapricor Therapeutics granted orphan status for DMD treatment
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use